abstract |
The present invention is achieved without affecting their maturity, memory or proliferation by reducing the number of circulating and infiltrating T and B lymphocytes that are agonists of the G protein coupled receptor S1P1 / EDG1 Provided are novel compounds of formula (I) having a potent and long-lasting immunosuppressive effect. Reduction of circulating T / B lymphocytes as a result of S1P1 / EDG1 agonism suppresses such compounds, possibly in conjunction with the observed improvement in endothelial cell layer function associated with S1P1 / EDG1 activation. It is useful for treating non-inflammatory diseases and for improving vascular functionality. [Selection figure] None |